Literature DB >> 9855040

A global model to define the behavior of partial agonists (bell-shaped dose-response inducers) in pharmacological evaluation of activity in the presence of the full agonist.

K Ghosh1, E S Shen, B J Arey, F J López.   

Abstract

The dose-response models for full agonists and for a particular type of partial agonist can be described by sigmoidal curves and bell-shaped curves, respectively. The methods currently used to evaluate the interaction of a full agonist and a partial agonist require a large number of experimental units and base their analysis on nonlinear regression analysis, which may not be statistically appropriate. We propose an appropriate design and a global nonlinear model to evaluate such interactions. The new model allows us to estimate the interaction parameters and the parameters that characterize the individual partial agonist curve and the full agonist curve.

Mesh:

Substances:

Year:  1998        PMID: 9855040     DOI: 10.1080/10543409808835266

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  3 in total

1.  Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells.

Authors:  Megan E Cavet; Karen L Harrington; Keith W Ward; Jin-Zhong Zhang
Journal:  Mol Vis       Date:  2010-09-02       Impact factor: 2.367

2.  A monoclonal antibody targeting amyloid β (Aβ) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer's disease.

Authors:  Kameran Lashkari; Gianna Teague; Hong Chen; Yong-Qing Lin; Sanjay Kumar; Megan M McLaughlin; Francisco J López
Journal:  PLoS One       Date:  2018-05-21       Impact factor: 3.240

3.  BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.

Authors:  Jin-Zhong Zhang; Megan E Cavet; Karl R VanderMeid; Mercedes Salvador-Silva; Francisco J López; Keith W Ward
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.